Cisplatin and Oral S-1 Show Feasibility in Cancer Patients with Severe Liver Dysfunction
A seven-year prospective trial shows that oral S-1 plus cisplatin preserves overall 5-FU exposure and manageable toxicity in cancer patients ...
A seven-year prospective trial shows that oral S-1 plus cisplatin preserves overall 5-FU exposure and manageable toxicity in cancer patients ...
A double-blind crossover trial in 15 healthy volunteers found that intravenous apelin-13, at both high and low doses, did not ...
We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.
Success! An email was just sent to confirm your subscription. Please find the email now and click 'Confirm' to start subscribing.
Bioengineer.org © Copyright 2023 All Rights Reserved.
Bioengineer.org © Copyright 2023 All Rights Reserved.